cGAS-STING: How Mitochondrial DNA Triggers Inflammation

Cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING) turn misplaced DNA into an innate immune alarm, and stressed mitochondria can supply that DNA. R

In this post, we will discuss how mitochondrial DNA (mtDNA) escapes damaged mitochondria, activates type I interferon (IFN-I) and inflammasome signaling, intersects with aging, auto-inflammatory disease, and neuroinflammation, and where Jacob's Micro-Sepsis (MSS) and Junction Dysfunction (JD) interpretation begins.

---

What Is cGAS-STING?

Cyclic GMP-AMP synthase (cGAS) is a cytosolic sensor that binds double-stranded DNA (dsDNA) in the wrong cellular compartment. R

cGAS converts ATP and GTP into the second messenger cyclic GMP-AMP (cGAMP) after it binds DNA. R

cGAMP binds stimulator of interferon genes (STING), an adaptor located in the endoplasmic reticulum (ER), and activates STING trafficking into downstream signaling compartments. R

Activated STING recruits TANK-binding kinase 1 (TBK1) and activates interferon regulatory factor 3 (IRF3), which moves into the nucleus and promotes type I interferon production. R

STING also activates nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase signaling, which adds inflammatory cytokines and chemokines to the interferon response. R

The first major output is IFN-I, especially interferon beta, which can act on the same cell and neighboring cells through the type I interferon receptor (IFNAR). R

IFNAR activates Janus kinase (JAK) and signal transducer and activator of transcription (STAT) proteins, which assemble an interferon-stimulated gene program that changes antiviral, inflammatory, and regulatory cell behavior. R

This pathway evolved to detect microbial DNA, but cGAS can also respond to endogenous DNA released from mitochondria or damaged nuclei. R

That distinction matters because the same pathway that protects against infection can become a source of sterile inflammation when self-DNA is repeatedly misplaced. R

How Mitochondrial DNA Escapes

Mitochondrial DNA normally remains enclosed inside mitochondria, which gives the cell a way to use a bacteria-like genome without constantly exposing it to cytosolic DNA sensors. R

Mitochondria contain their own genome because they evolved from bacterial ancestors, so misplaced mtDNA carries molecular features that can resemble microbial danger signals to innate immunity. R

Mitochondrial stress can weaken this compartmentalization through oxidative damage, calcium dysregulation, membrane permeabilization, defective mitophagy, or cell death. R

One experimentally defined route involves opening of the mitochondrial permeability transition pore (mPTP) and oligomerization of the voltage-dependent anion channel (VDAC) in the outer mitochondrial membrane. R

This route can release fragmented oxidized mitochondrial DNA (Ox-mtDNA), which has stronger inflammatory activity than intact, well-compartmentalized mtDNA in the models studied. R

Another route involves partial mitochondrial outer membrane permeabilization through BAX and BAK macropores during cellular senescence. R

The important detail is that partial membrane damage does not always kill the cell immediately, which allows a stressed but surviving cell to continue releasing inflammatory signals. R

Defective mitochondrial quality control can also allow mtDNA to accumulate in autophagic compartments and activate Toll-like receptor 9 (TLR9), as shown in pressure-overloaded mouse hearts with impaired lysosomal DNA degradation. R

That heart study was animal-only evidence, and it involved TLR9 more directly than cGAS-STING. R

MtDNA can also reach the extracellular space as free DNA, protein-bound fragments, or cargo inside extracellular vesicles, after which the receiving cell may route it through endosomal or cytosolic DNA sensors. R

The route, size, oxidation state, and cellular location of the DNA help determine which inflammatory program is activated. R

How Leaked Mitochondrial DNA Triggers Inflammation

Leaked mtDNA is not one uniform signal because the cytosol, endosome, and extracellular space contain different sensors and signaling machinery. R

The Cytosolic cGAS Route

When mtDNA reaches the cytosol, cGAS can bind it and generate cGAMP. R

cGAMP activates STING, which recruits TBK1 and activates IRF3 to promote IFN-I production. R

The same STING complex can activate NF-κB, producing a broader inflammatory program than interferon alone. R

The resulting interferon-stimulated genes can increase antiviral defenses, alter antigen presentation, and change the activation state of nearby immune and tissue cells. R

The NLRP3 Route

The NOD-like receptor protein 3 inflammasome (NLRP3) is a cytosolic protein complex that processes inflammatory cytokines after sensing cellular danger. R

Ox-mtDNA can bind NLRP3 and promote caspase-1 activation, which converts pro-interleukin-1 beta and pro-interleukin-18 into their active forms. R

The same process can activate gasdermin D pores and promote pyroptotic cell death, which releases additional inflammatory material into the tissue. R

In macrophage and mouse models, mPTP and VDAC-dependent escape of Ox-mtDNA activated both NLRP3 and cGAS-STING signaling. R

The TLR9 Route

When mtDNA is delivered into an endosome, TLR9 can recognize it and activate NF-κB-dependent cytokine production. R

The TLR9 route is especially useful for understanding why extracellular or autophagy-derived mtDNA can cause inflammation without directly entering the cytosol. R

This is also why an elevated inflammatory response does not automatically identify cGAS-STING as the only sensor involved. R

cGAS-STING, Inflammasomes, And Type I Interferon

The clean diagram is cGAS, cGAMP, STING, TBK1, IRF3, and IFN-I, but the biology is a network rather than a single straight line. R

Ox-mtDNA can activate cGAS-STING, NLRP3, and TLR9 through overlapping but non-identical routes. R

The cGAS-STING arm is more closely associated with IFN-I and interferon-stimulated genes, while NLRP3 is more closely associated with caspase-1, interleukin-1 beta, interleukin-18, and pyroptosis. R

NF-κB sits at an important intersection because STING can activate it directly, and NF-κB can provide the transcriptional priming required for stronger inflammasome responses. R

This creates a plausible pattern in which a person has both an antiviral-like interferon signature and an inflammasome-like cytokine signature without an active virus being the direct trigger. R

That sentence describes a mechanistic possibility, not a diagnostic rule, because many other sensors and inflammatory pathways can produce similar outputs. R

Transient activation can coordinate repair and host defense, while persistent activation can turn the same machinery into a source of tissue stress and immune miscalibration. R

Aging, Auto-Inflammatory Disease, And Neuroinflammation

Aging And Cellular Senescence

Cellular senescence is a durable cell-cycle arrest state that can include a senescence-associated secretory phenotype (SASP). R

In cultured cells and aged mice, partial BAX and BAK-mediated mitochondrial membrane permeabilization released mtDNA and activated cGAS-STING to drive the SASP. R

In a separate aging study, STING blockade reduced inflammatory phenotypes in senescent human cells and tissues and reduced age-associated inflammation in multiple mouse organs. R

The brain findings in that study were primarily animal evidence, with STING activation in aging microglia linked to reactive transcriptional states, neurotoxicity, and impaired memory in mice. R

This is a strong reason to study cGAS-STING in aging, but it is not proof that every feature of human aging is caused by mtDNA leakage or that long-term STING inhibition is safe. R

Auto-Inflammatory Disease

Rare human mutations show that excessive STING activity can cause disease even when there is no external DNA stimulus. R

Dominant gain-of-function variants in TMEM173, the gene that encodes STING, cause STING-associated vasculopathy with onset in infancy (SAVI), an interferonopathy with early systemic inflammation, vasculopathy, and interstitial lung disease. R

The original family study identified a constitutively active TMEM173 mutation in people with variable inflammatory and lupus-like manifestations. R

Loss of the cytosolic DNA exonuclease TREX1 can allow self-DNA to accumulate and drive STING-mediated inflammation. R

Biallelic variants in TREX1 and the RNASEH2A, RNASEH2B, or RNASEH2C genes are established causes of Aicardi-Goutières syndrome (AGS), a rare genetic interferonopathy that can resemble congenital viral infection. R

Heterozygous COPA variants can cause abnormal STING trafficking from the ER to the Golgi and increased interferon signaling in COPA syndrome. R

In human systemic lupus erythematosus, monocytes showed elevated cytosolic mtDNA and robust IFN-I production, while experiments in humanized lupus chimeras linked glycolytic lactate production to stronger cGAS activity. R

These rare genetic syndromes and autoimmune disease studies show that the pathway can be pathogenic, but they do not establish that all auto-inflammatory symptoms share one mtDNA cause. R

Neuroinflammation

Microglia are immune cells in the central nervous system, and aging-related cGAS-STING activation in microglia can produce inflammatory signals that affect nearby neurons and astrocytes. R

The strongest direct evidence for mtDNA-driven brain effects comes from mouse work showing that cytosolic DNA from perturbed mitochondria activated cGAS in old microglia and contributed to neurotoxic states and cognitive decline. R

The pathway may be protective during some infections and damaging when activated chronically, so the phrase neuroinflammation by itself does not tell you whether STING should be increased or decreased. R

The integrated stress response also intersects with this biology, because a bacterial genotoxin study found that mitochondrial DNA damage activated STING-linked inflammatory components alongside the GCN2-mediated stress response, although the evidence was mechanistic and context-specific. R

How This Fits The Junction Dysfunction Framework

Established Biology

The established biology is that mitochondrial stress can release mtDNA, misplaced mtDNA can activate cGAS-STING, and sustained activation can amplify interferon and inflammatory signaling. R

Those findings connect naturally to mitochondrial membrane integrity, redox buffering, mitophagy, and immunometabolism, which are also discussed in the SS-31 post, the MOTS-c post, the glutathione guide, and the itaconate post. R

Those adjacent mechanisms should not be confused with evidence that any one peptide, antioxidant, or immunometabolite has been proven to normalize cGAS-STING in people. R

Jacob's Hypothesis

Junction Dysfunction (JD) is Jacob's umbrella framework for compromised glycocalyx function, with Transient Capillary Leak Syndrome (TCLS) and Micro-Sepsis (MSS) as interacting sub-pathologies.

Jacob coined the terms TCLS and MSS, and his hypothesis is that persistent glycocalyx stress, microvascular fluid shifts, hypoxia, and innate immune activation can keep mitochondria under enough pressure to increase mtDNA release.

In that framing, cGAS-STING is not the root cause of JD, but a downstream alarm and amplifier that can help explain why mitochondrial stress becomes inflammatory instead of remaining a local metabolic problem. R

This is Jacob's hypothesis, not a demonstrated causal chain in human JD, and the current literature does not prove that TCLS or MSS activates cGAS-STING in every chronically ill person.

The practical distinction is important because treating a downstream DNA-sensing pathway without addressing the upstream mitochondrial or tissue stress could leave the trigger in place. R

Safety And Evidence Limits

The cGAS-STING pathway is not simply a harmful inflammation switch because it contributes to antiviral defense, immune surveillance, and antitumor responses. R

Broadly suppressing STING could theoretically reduce necessary host defense, while broadly activating it could worsen sterile inflammation, so the right direction depends on tissue, timing, and disease context. R

Most proposed cGAS-STING interventions for chronic inflammatory and aging-related disease remain preclinical, disease-specific, or early translational research. R

Research inhibitors that work in cell culture or animal models do not establish safe human dosing, long-term safety, or clinical benefit. R

Rare STING gain-of-function and DNA-clearance disorders are useful proof of mechanism, but their biology is much more extreme than ordinary genetic variation. R

Symptoms such as fatigue, brain fog, pain, or cognitive change cannot identify mtDNA leakage or cGAS-STING activation on their own.

I would not use this pathway as a reason to self-prescribe immune-suppressing drugs, experimental STING inhibitors, or aggressive mitochondrial stressors.

Mechanisms Of Action

Simple:

• Mitochondria under stress can release their DNA into places where the immune system can see it. R
• cGAS reads misplaced DNA and converts ATP and GTP into the messenger cGAMP. R
• cGAMP activates STING, which turns on interferon and inflammatory gene programs. R
• Oxidized mtDNA can also activate NLRP3, so the output can include both interferon and inflammasome cytokines. R

Advanced:

• BAX and BAK-mediated mitochondrial permeabilization can create macropores that release mtDNA during senescence or apoptotic stress, even before the whole cell dies. R
• cGAS-cGAMP-STING-TBK1-IRF3 signaling converts cytosolic dsDNA into IFN-I production through cGAS enzymatic activity, STING trafficking, TBK1 activation, and IRF3 nuclear translocation. R
• NF-κB and NLRP3 convergence allows STING-associated transcriptional priming to overlap with Ox-mtDNA-driven caspase-1 activation, interleukin-1 beta release, interleukin-18 release, and pyroptosis. R
• Senescence-associated secretory phenotype (SASP) signaling can be sustained when sublethal mitochondrial apoptotic stress repeatedly releases mtDNA into the cytosol and activates cGAS-STING. R
• TLR9 endosomal DNA sensing provides a parallel route for extracellular or autophagy-derived mtDNA to activate NF-κB-dependent inflammation without requiring direct cytosolic cGAS engagement. R

Genetics

TMEM173

TMEM173 encodes STING, the ER adaptor that receives cGAMP after cGAS detects cytosolic DNA. R

Dominant gain-of-function variants in TMEM173 can cause SAVI through ligand-independent or excessive STING activation. R

These are rare pathogenic variants and should not be confused with a routine consumer genetics result suggesting ordinary inflammation risk. R

TREX1

TREX1 encodes a three-prime repair exonuclease that helps prevent cytosolic self-DNA from accumulating. R

Loss-of-function TREX1 variants can increase self-DNA sensing and contribute to STING-mediated interferonopathy. R

RNASEH2A

RNASEH2A encodes one subunit of the RNase H2 complex, and biallelic variants are an established cause of AGS. R

RNASEH2B

RNASEH2B encodes another RNase H2 subunit, and biallelic variants can produce a later-onset AGS phenotype with variable neurologic severity. R

RNASEH2C

RNASEH2C encodes the third major RNase H2 subunit, and biallelic variants are associated with AGS and interferon-driven neurologic disease. R

COPA

COPA encodes coatomer protein complex subunit alpha, which helps regulate intracellular trafficking between the ER and Golgi. R

Heterozygous COPA variants can impair STING retrieval from the Golgi and increase IFN-I signaling in COPA syndrome. R

TOP1MT

TOP1MT encodes mitochondrial topoisomerase I, a protein involved in maintaining mitochondrial DNA topology. R

A functional study of a P193L TOP1MT variant found that reduced TOP1MT activity could increase cytosolic mtDNA and activate cGAS-STING in a family with early-onset autoimmune disease, but this is an emerging gene-disease association rather than a routine clinical interpretation. R

More Research

• Aging studies need human intervention data because the strongest direct evidence for mtDNA-driven cGAS-STING effects on old microglia, neurotoxicity, and memory currently comes from mice. R
• Cellular specificity research needs to explain why similar mitochondrial stress routes cGAS toward IFN-I in one context, NLRP3 toward interleukin-1 beta and interleukin-18 in another, and TLR9 toward endosomal NF-κB signaling in a third. R
• Mitochondrial quality control may be a safer upstream target than blanket STING inhibition if damaged mitochondria can be repaired or removed before mtDNA escapes. R
• Neuroinflammation research still needs to separate protective antiviral STING activity from chronic microglial activation that contributes to neurodegeneration. R
• Therapeutic targeting must preserve enough cGAS-STING activity for infection and tumor surveillance while reducing pathological self-DNA signaling. R
• Tissue context matters because findings from SLE monocytes, aging microglia, senescent fibroblasts, cardiomyocytes, and macrophages cannot be treated as interchangeable human disease models. R